Organisation paid for research Program year 2025 Source: CMS Open Payments

Valley Clinical Trials Covina

Neither a doctor nor a teaching hospital

Research payments

$1,473,216

12 payments

Through program year 2025, Valley Clinical Trials Covina is reported as receiving $1,473,216 in research payments, across 12 payments.

By program year

5 rows

Year	Kind	Amount	Payments
2025	Research	$526,558	4
2024	Research	$486,617	3
2023	Research	$286,724	3
2022	Research	$173,203	1
2021	Research	$114	1

Breakdown

Who paid Research payments · program years 2021–2025

Novartis Pharmaceuticals Corporation $1,473,216 12 payments

Studies the money was for Research payments · program years 2021–2025

Hps-4/Timi 65/Orion-4: A Double-Blind Randomized Placebo-Controlled Trial Assessing the Effects of Inclisiran on Clinical Outcomes Among People With Atherosclerotic Cardiovascular Disease $1,223,300 6 payments
A Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Effect of Inclisiran on Preventing Major Adverse Cardiovascular Events in High-risk Primary Prevention Patients (VICTORION-1 PREVENT) $217,184 3 payments
A randomized double-blind, placebo-controlled, multicenter study to evaluate the efficacy, safety and tolerability of pelacarsen (TQJ230) in US Black/African American & Hispanic patient populations with elevated Lp(a) and established atherosclerotic cardi $16,074 1 payment
Evaluation of Inclisiran Versus Placebo for the Prevention of Major Adverse Cardiovascular and Limb Events in Patients Undergoing Percutaneous Coronary Intervention or Peripheral Endovascular Intervention (V-INTERVENTION) $13,662 1 payment
A randomized double-blind, placebo-controlled, multicenter study to evaluate the efficacy, safety and tolerability of pelacarsen (TQJ230) in US Black/African American & Hispanic patient populations with elevated Lp(a) and established atherosclerotic cardiovascular disease $2,996 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.